Juvenile Localized Scleroderma from a Pediatric Rheumatology Perspective: A Single-Center Experience
Juvenile Localized Scleroderma
DOI:
https://doi.org/10.5281/zenodo.7718553Keywords:
Juvenile localized scleroderma, morphea, treatmentAbstract
Aim: To evaluate juvenile localized scleroderma, which is a disease with high rates of cosmetic and functional sequelae in children, from a pediatric rheumatology perspective.
Materials and Methods: We retrospectively investigated the data of patients who were diagnosed with juvenile localized scleroderma (JLS) in our pediatric rheumatology clinic between 2015 and 2022, were aged <18 years and attended their follow-ups regularly. Demographic, clinical, treatment-related, and prognostic data of the patients were included.
Results: Among the 19 patients diagnosed with JLS, 12 (63.2%) were female, and 7 (36.8%) were male. The female-to-male ratio in the sample was 1.7. Eight (42.1%) patients had circumscribed JLS, 8 (42.1%) had linear JLS, 2 (10.6%) had mixed JLS, and 1 (5.3%) had generalized JLS. The mean age of onset of symptoms in the patients was 8.2±5.5 years, while their mean age of diagnosis was 9.4±4.9 years. The most frequently involved anatomical regions were the extremities, whose involvement was found in 15 (78.9%) patients. The prevalence of lesions crossing joints was 57.9%, and joint damage was seen in 21.1% of the patients. The rate of cosmetic sequelae was 73.7%. There was antinuclear antibody positivity in 52.6% of the patients. Systemic involvement did not occur in any patients during their follow-ups. The most frequently used treatment agent was methotrexate. Complete remission was achieved in 2 (10.6%) patients.
Conclusion: As it can lead to high degrees of cosmetic and functional sequelae, it is needed to diagnose juvenile localized scleroderma early and start an aggressive treatment in the early period. To avoid wasting time, it is important, especially for pediatricians, to immediately order biopsies from suspected lesions or refer these patients to pediatric rheumatology clinics.
Downloads
References
References
Zulian F, Lanzoni G, Castaldi B, et al. Systemic sclerosis sine scleroderma in children. Rheumatology (Oxford). 2022; 61(6): 2555-2562. doi: 10.1093/rheumatology/keab738.
Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of Juvenile Systemic Sclerosis. Front Immunol. 2019; 10: 1352. doi: 10.3389/fimmu.2019.01352.
Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. Curr Opin Rheumatol. 2013; 25(5): 643-50. doi: 10.1097/BOR.0b013e3283641f61.
Guariso G, Conte S, Galeazzi F, Vettorato MG, Martini G, Zullian F. Esophageal involvement in juvenile localized scleroderma: a pilot study. Clin Exp Rheumatol. 2007;25: 786–9.
Foeldvari I. New developments in juvenile systemic and localized scleroderma. Rheum Dis Clin North Am. 2013; 39(4): 905-20. doi: 10.1016/j.rdc.2013.05.003.
Zulian F, Vallongo C, Woo P, et al; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005; 52(9): 2873-81. doi: 10.1002/art.21264.
Zulian F, Athreya BH, Laxer R, et al; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006; 45(5): 614-20. doi: 10.1093/rheumatology/kei251.
Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008; 20(5): 601-7. doi: 10.1097/BOR.0b013e328309a5eb.
Weber K. Is juvenile localized scleroderma related to Lyme borreliosis? J Am Acad Dermatol. 2009 ;61(5): 901. doi: 10.1016/j.jaad.2009.05.022.
Li S, Pope E. Localized scleroderma. In: Petty R, Laxer R, Lindsley C, Wedderburn L, editors. Textbook of pediatric rheumatology. 7th ed. Elsevier; 2015. p. 406–15.
Li SC, Zheng RJ. Overview of Juvenile localized scleroderma and its management. World J Pediatr. 2020;16(1): 5-18. doi: 10.1007/s12519-019-00320-9.
Rőcken M and Ghoreschi K. Morphea and lichen sclerosus. In: Bolognia JL, et al. Dermatology. 2nd ed. Mosby Elsevier, Spain 2008.p.1469-76.
Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24: 73-80.
Vallongo C, Woo P, Russo R, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52: 2873-81.
Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F. Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review. Autoimmun Rev. 2018; 17(7): 727-734. doi: 10.1016/j.autrev.2018.02.004.
Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019; 78(8): 1019-1024. doi: 10.1136/annrheumdis-2018-214697.
İzol B, Sarıcaoğlu H, Başkan EB, et al. Pediatrik morfea (lokalize skleroderma) 14 olguya ait epidemiyolojik klinik ve laboratuar bulguları. Türkderm 2011; 45: 132- 6.
Bulur I, Erdoğan HK, Karapınar T, Saracoglu ZN. Morphea in Middle Anatolia, Turkey: a 5-year single-center experience. Postepy Allegol 2017; 34: 334-8.
Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44: 1359-1362.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 1996; 22: 751-764.
Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994; 23: 328–40.
Vancheeswaran R, Black CM, David J et al. Childhood onset scleroderma: is it different from adult onset disease. Arthritis Rheum 1996; 39: 1041–49.
Lo CY, Shyur SD, Chu SH, et al. Juvenile scleroderma: experience in one institution. Asian Pac J Allergy Immunol. 2010; 28(4): 279-86.
Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003; 13: 171-6.
Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr 2013; 104: 654-66.
Koç S, Uzun S. Skleroderma. Turkiye Klinikleri J Dermatol Special Topics 2014; 7: 33-43.
Wu EY, Li SC, Torok KS, Virkud YV, Fuhlbrigge RC, Rabinovich CE; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators. Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. ACR Open Rheumatol. 2019 Apr 10;1(2):119-124. doi: 10.1002/acr2.1019.
Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatriccases. Arch Dermatol 2009; 145: 545-50.
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008; 59(3): 385-96. doi: 10.1016/j.jaad.2008.05.005.
Kashem SW, Correll CK, Vehe RK, Hobday PM, Binstadt BA, Maguiness SM. Inflammatory arthritis in pediatric patients with morphea. J Am Acad Dermatol. 2018; 79(1): 47-51.e2. doi: 10.1016/j.jaad.2018.03.005.
Rosenberg AM, Uziel Y, Krafchik BR et al. Antinuclear antibodies in children with localized scleroderma. J Rheumatol 1994; 22: 2337–43.
Blaszczyk M, Jarzabek-Chorleska M, Jablonska S. Relationship between cutaneous and systemic scleroderma. Are immunopathological studies helpful in evaluating transition of cutaneous to systemic scleroderma? Przegl Dermatol 2000; 2: 119–25
Rondinone R, Germino M, Sartori E et al. Autoimmune disorders in localized scleroderma. Arch Dermatol Res 1990; 282: 477–9.
Jablonska S, Chorzelski TP, Blaszczyk M. Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 1993; 10: 407–21.
Dytoc MT, Kossintseva I, Ting PT: First case series on the use of calcipotriolbetamethasone dipropionate for morphoea. Br J Dermatol 2007; 157: 615-8.
Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM: Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollientcontrolled pilot study. Am J Clin Dermatol 2009; 10: 181-7.
Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM: First case series on the use of imiquimod for morphoea. Am J Clin Dermatol 2005; 153: 815-20.
Parlak N, Akay BN, Erdi Şanlı H, Akyol A. The clinical features, laboratory findings, treatment and follow-up results of patients with morphea. Turkderm-Turk Arch Dermatol Venereol 2013; 47; 209-213. doi:10.4274/turkderm.05657.
Piram M, McCuaig CC, Saint‐Cyr C, et al. Short‐and long‐term outcome of linear morphoea in children. British Journal of Dermatology, 2013; 169(6): 1265-1271.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chronicles of Precision Medical Researchers
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
